Interview with Dr James Garner, CEO of Kazia Therapeutics
-
Regulatory September 15, 2023Delisting of Vivesto’s shares from Frankfurt Stock Exchange effective as of 15 September 2023
-
Regulatory August 24, 2023Interim report for the period January 1, 2023 – June 30, 2023
-
Non Regulatory August 4, 2023Vivesto announces early termination of patient enrollment in the investigator-initiated Phase 1b Docetaxel micellar study
Vivesto published its Q2 report for 2023 on August 24, 2023, at 08.00 am CEST.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program